....and yet another stem cell partnership (from an investment house). Its as if the investment community (outside of Australia) actually have a clue of the potential of regenrative medicine's effects on the landscape of medical treatments:
https://www.fiercebiotech.com/cro/ncardia-inks-60m-funding-deal-to-expand-discovery-and-commercial-production-services-for-stem
Roche "At Roche we are utilizing the enormous potential of human stem cells to test potential new drugs in vitro"
Bristol-Myers Squibb "cell-based therapies that use a person’s own cells are unlocking new potential in the fight against some of the most difficult-to-treat cancers...autologous chimeric antigen receptor (CAR) T cell therapy"
Pfizer "for more than a decade, Pfizer has been using animal or adult stem cells in its laboratories to help screen new compounds and identify safer and more effective medicines"
Eli Lilly - stem cells in diabetes; Astra Zenica - oncology etc, etc, etc
Partnerhsip between:
Biogen/Sangamo
J&J (Janssen)/Fate
Novartis/Sangamo
Bayer/Atara
Sanofi/Aventis
Novartis/Mesoblast (maybe!)
Fujifilm/Cynata
Sanofi/Kadmon
etc, etc.
The use of stem-cells, be they tissue specific, emryonic, and autologous, induced pluripotent or otherwise are taking off in development.
Johnson and Johnson's vaccine received a bit of furore over using fetal (retinal) embryonic cells in the research that led to its vaccines. Ironically the media overlooked Pfizer/Moderna's use of the fetal cell line HEK-293 in the confirmation phase to ensure the vaccines work.
Emryonic and other stem-cells are, quietly, increasingly being used in the labs of big Pharma in much of their research. There is little chance J&J leaves this very morally acceptable treatment of using a patients own stem-cells in a safe and very convenient way to address degenerative tendons. Its such an easy, uncontentioius and quick commercial possibility compared to most stem-cell treatments.
- Forums
- ASX - By Stock
- OCC
- J&J Partnership
J&J Partnership, page-354
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OCC (ASX) to my watchlist
|
|||||
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $78.59M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 13513 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 5465 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 13513 | 0.370 |
3 | 40724 | 0.365 |
8 | 118767 | 0.360 |
5 | 59319 | 0.355 |
7 | 91882 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 5465 | 2 |
0.380 | 23190 | 3 |
0.385 | 10493 | 1 |
0.390 | 29373 | 5 |
0.395 | 30226 | 2 |
Last trade - 12.24pm 23/08/2024 (20 minute delay) ? |
Featured News
OCC (ASX) Chart |
Day chart unavailable
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online